What is the mechanism by which leukotriene C4 (LTC4) binding to an intracellular cysteinyl‑leukotriene receptor (cysLTR) induces interleukin‑4 (IL‑4) production independent of the Gq heterotrimeric protein?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

LTC4-CysLTR Mediated IL-4 Production: Intracellular Signaling Mechanism

The mechanism by which LTC4 induces IL-4 production involves binding to an unidentified intracellular cysteinyl leukotriene receptor (distinct from the known cell-surface CysLT1R and CysLT2R) that signals through a pertussis toxin-sensitive G protein pathway, independent of the classical Gq heterotrimeric protein, to selectively trigger vesicular transport-mediated IL-4 secretion from eosinophils.

The Intracrine Signaling Pathway

The key mechanistic insight comes from experimental work demonstrating that LTC4 functions as an intracrine (intracellular) mediator rather than through classical paracrine (extracellular) signaling 1. This represents a fundamentally different mode of action from the well-characterized extracellular cysteinyl leukotriene receptors.

Critical Experimental Evidence

The mechanism was elucidated through several key observations 1:

  • Exogenous LTC4, LTD4, or LTE4 applied to intact eosinophils do not elicit IL-4 release, indicating the receptor is not accessible from the cell surface
  • Only after membrane permeabilization do LTC4 and LTD4 gain access to their receptor and stimulate IL-4 (but not RANTES) release
  • LTC4 is 10-fold more potent than LTD4 at this intracellular receptor, with optimal activity at very low concentrations (0.3-3 nM)
  • At higher concentrations (>3 nM), LTC4 paradoxically inhibits IL-4 release, suggesting a biphasic dose-response relationship

The Unidentified Receptor

This intracellular cysLTR is pharmacologically distinct from both CysLT1R and CysLT2R 1. Specifically:

  • Inhibitors of CysLT1R and CysLT2R do not block LTC4-elicited IL-4 release from permeabilized eosinophils
  • The receptor signals through a pertussis toxin-sensitive G protein, indicating involvement of Gi/Go proteins rather than Gq
  • This represents a novel, as-yet-uncharacterized receptor that remains molecularly unidentified

Physiological Context

The intracellular LTC4 signaling occurs in the context of eosinophil activation 1:

  1. Stimuli (IL-16, eotaxin, RANTES) activate eosinophils
  2. LTC4 synthesis occurs at intracellular lipid bodies via 5-lipoxygenase
  3. Intracellular LTC4 binds the unidentified cysLTR
  4. Selective IL-4 release occurs via vesicular transport-mediated degranulation
  5. LTC4 export through ATP-binding cassette transporters terminates the signal

Regulatory Mechanisms

Blocking LTC4 export paradoxically inhibits IL-4 release 1. When LTC4 export inhibitors were used, intracellular LTC4 accumulated to higher concentrations, which then inhibited eotaxin-elicited IL-4 release. This confirms the biphasic dose-response relationship and suggests that controlled LTC4 levels are critical for proper signaling.

Biochemical Pathway Context

While the guidelines describe LTC4 biosynthesis in detail 2, they focus on extracellular LTC4 as a biomarker of mast cell activation rather than its intracrine signaling role. The standard pathway involves:

  • Arachidonic acid → 5-lipoxygenase → LTA4 → LTC4 synthase → LTC4
  • Secretion through ATP-binding cassette transporters 1 and 4
  • Rapid extracellular metabolism to LTD4 and then LTE4

Clinical Implications

The intracrine LTC4-IL-4 pathway has important implications:

  • 5-lipoxygenase inhibitors block IL-4 release 1, suggesting therapeutic potential
  • This mechanism may contribute to eosinophil-driven allergic inflammation beyond classical leukotriene receptor antagonism
  • Standard cysLT receptor antagonists (montelukast, zafirlukast) targeting CysLT1R 2 would not block this intracellular pathway

Key Caveats

  • The molecular identity of the intracellular cysLTR remains unknown despite the functional characterization
  • This mechanism has been primarily demonstrated in eosinophils; whether it operates in other cell types is unclear
  • The selective regulation of IL-4 (but not RANTES) release suggests highly specific downstream signaling that is incompletely understood
  • Recent structural work on CysLT2R 3 describes an allosteric binding site for CysLTs, but this is still an extracellular receptor mechanism distinct from the intracellular pathway described here

References

Related Questions

In a patient three days after total knee replacement who is on rivaroxaban (Xarelto) for VTE prophylaxis and now presents with mixed hematochezia and epigastric pain, without abdominal pain, nausea, vomiting, painful defecation, diarrhea, constipation, straining, or rectal lesions, what are the appropriate next diagnostic and management steps?
Why does the mitral regurgitation murmur remain essentially unchanged during expiration, and what is the mechanism?
How important is it to start antifibrotic therapy when fibrous tissue is identified on a chest CT, and is early initiation essential?
How should baseline troponin T be managed and what treatment is recommended for an asymptomatic patient with chronically mildly elevated troponin T?
How can one progress from a child to become a professional clinical pharmacist?
How should a delayed-release formulation be dosed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.